Clinical Trials
2 trialsNCT04248829 2026-05-28
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
Phase 3 Completed
NCT01610336 2021-04-08
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Phase 2 Completed